The in vitro diagnostic medical devices regulation (IVDR) will take effect in May 2022. This regulation has a large impact on both the manufacturers of in vitro diagnostic medical devices (IVD) and clinical laboratories. For clinical laboratories, the IVDR poses restrictions on the use of laboratory developed tests (LDTs). To provide a uniform interpretation of the IVDR for colleagues in clinical practice, the IVDR Task Force was created by the scientific societies of laboratory specialties in the Netherlands. A guidance document with explanations and interpretations of relevant passages of the IVDR was drafted to help laboratories prepare for the impact of this new legislation. Feedback from interested parties and stakeholders was collected and used to further improve the document. Here we would like to present our approach to our European colleagues and inform them about the impact of the IVDR and, importantly we would like to present potentially useful approaches to fulfill the requirements of the IVDR for LDTs.
Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
1. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Off J European Union L 1998;331:1–37.Search in Google Scholar
2. Regulation (EU) 2017/746 of the European Parliament and of the council of 5 April 2017 on in vitro diagnostic medical devices and repealing directive 98/79/EC and commission decision 2010/227/EU. Off J Eur Union 2017;117:176–332.Search in Google Scholar
3. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending directive 2001/83/EC, regulation (EC) No 178/2002 and regulation (EC) No 1223/2009 and repealing council directives 90/385/EEC and 93/42/EEC. Off J Eur Union 2017 L 117: 1-175, eur-lex. europa. eu/eli/reg/2017/745/ 2017 [Accessed 10 Apr 2020].Search in Google Scholar
4. Steele, GD, Fehring, TK, Odum, SM, Dennos, AC, Nadaud, MC. Early failure of articular surface replacement XL total hip arthroplasty. J Arthroplasty 2011;26:14–8. https://doi.org/10.1016/j.arth.2011.03.027.Search in Google Scholar PubMed
7. COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning medical devices. 1993.Search in Google Scholar
8. Spencer, S. The essential IVDR and the challenges it presents rockville: regulatory affairs professionals society; 2019. Available from: https://www.raps.org/news-and-articles/news-articles/2019/9/the-essential-ivdr-and-the-challenges-it-presents.Search in Google Scholar
9. Cobbaert, C, Smit, N, Gillery, P. Metrological traceability and harmonization of medical tests: a quantum leap forward is needed to keep pace with globalization and stringent IVD-regulations in the 21st century! Clin Chem Lab Med 2018;56:1598–602. https://doi.org/10.1515/cclm-2018-0343.Search in Google Scholar PubMed
10. Haahr, T. Parliament decides to postpone new requirements for medical devices; 2020. Available from: https://www.europarl.europa.eu/news/en/press-room/20200415IPR77113/parliament-decides-to-postpone-new-requirements-for-medical-devices.Search in Google Scholar
11. van Drongelen, A, de Bruijn, A, Pennings, J, van der Maaden, T. The impact of the new European IVD-classification rules on the notified body involvement; a study on the IVDs registered in the Netherlands. Bilthoven: National Institute for Public Health and the Environment; 2018.Search in Google Scholar
13. Vermeersch, P, Van Aelst, T, Dequeker, EMC. The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care. Clin Chem Lab Med 2020;59:101–6.10.1515/cclm-2020-0804Search in Google Scholar PubMed
14. Le Goff, C, Farre-Segura, J, Stojkovic, V, Dufour, P, Peeters, S, Courtois, J, et al.. The pathway through LC-MS method development: In-house or ready-to-use kit-based methods? Clin Chem Lab Med 2021;59:101–6. https://doi.org/10.1515/cclm-2019-0916.Search in Google Scholar PubMed
15. Ko, DH, Cho, EJ, Lee, W, Chun, S, Min, WK. Accuracy evaluation of Roche and Siemens tacrolimus and cyclosporine assays in comparison with liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest 2018;78:431–8. https://doi.org/10.1080/00365513.2018.1472801.Search in Google Scholar PubMed
16. Zhou, P, Yang, XL, Wang, XG, Hu, B, Zhang, L, Zhang, W, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. https://doi.org/10.1038/s41586-020-2012-7.Search in Google Scholar PubMed PubMed Central
17. Corman, VM, Landt, O, Kaiser, M, Molenkamp, R, Meijer, A, Chu, DK, et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25. https://doi.org/10.2807/1560-7917.es.2020.25.3.2000045.Search in Google Scholar
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2020-1384).
© 2020 Walter de Gruyter GmbH, Berlin/Boston